Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1456033 | 0.97 | GNAI3 (0.38) | CHRNA7CYP2D6GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL222616 | 0.97 | GNAI3 (0.38) | CHRNA7CYP2D6GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL3410008 | 0.95 | HRH3 (0.33) | CHRNA7CYP2D6GNAI3GNAO1GNAI1 | |
| SCHEMBL12209129 | 0.91 | HRH3 (0.33) | CHRNA7CYP2D6GNAI3GNAO1GNAI1 | |
| SCHEMBL22253854 | 0.91 | HRH3 (0.33) | CHRNA7CYP2D6GNAI3GNAO1GNAI1 | |
| SCHEMBL22752741 | 0.89 | HRH3 (0.34) | CYP2D6HRH3KCNH2 | |
| SCHEMBL22314113 | 0.89 | HRH3 (0.34) | CYP2D6HRH3KCNH2 | |
| SCHEMBL21291314 | 0.87 | OPRM1 (0.35) | HRH3 | |
| SCHEMBL1306188 | 0.84 | — | — | |
| SCHEMBL2428595 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1019 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368650-A1 | 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-12-04 | — | — | US | claimed |
| WO-2025203062-A1 | INDOLE-BASED SMALL MOLECULE ANTIVIRALS AGAINST SARS-COV-2 | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2025-10-02 | — | — | WO | claimed |
| CN-114761404-B | Substituted bicyclic heteroaryl compounds | 百时美施贵宝公司 | 2025-02-21 | — | — | CN | claimed |
| CN-118307268-A | Radiation-resistant high-temperature-resistant fireproof plate and preparation method thereof | 威尔邦江阴防火板有限公司 | 2024-07-09 | — | — | CN | claimed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | claimed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | claimed |
| EP-4166553-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-04-19 | — | — | EP | claimed |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) | 2022-09-08 | — | — | US | claimed |
| CN-114728009-A | Preventing or treating diseases and disorders associated with tissue damage | 李晓祥 | 2022-07-08 | — | — | CN | claimed |
| CN-113717156-A | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| EP-1433788-A1 | Pyrazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-30 | — | — | EP | claimed |
| WO-2004050636-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | WO | claimed |
| EP-1426364-A1 | Imidazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-09 | — | — | EP | claimed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | claimed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | claimed |
| EP-1314733-A1 | Indole-2-carboxamides as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | claimed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | claimed |
| EP-1121372-A1 | ADENINE DERIVATIVES | Pfizer Limited (GB) | 2001-08-08 | — | — | EP | claimed |
| WO-2000023457-A1 | ADENINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-04-27 | — | — | WO | claimed |
| EP-0385044-A1 | New piperidine derivatives as antihistaminics | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1990-09-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, EGFR, WEE2 | CHRNA7 4664/4885CYP2D6 945/4885GNAI3 2264/4885 |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | CHRNA7 4817/4885CYP2D6 880/4885GNAI3 854/4885 |
| US-20250368650-A1 | 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS | ALK, TGFBR2, TGFBR1 | CHRNA7 2965/4885CYP2D6 3049/4885GNAI3 459/4885 |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | MST1, MSTN, MST1R | CHRNA7 3954/4885CYP2D6 4635/4885GNAI3 1899/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | CHRNA7 2384/4885CYP2D6 257/4885GNAI3 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.